Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway.
Saved in:
| Published in: | Journal of Food and Drug Analysis |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2025
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1864030189795672066 |
|---|---|
| collection | WordPress RSS FRELIP Feed Integration |
| container_title | Journal of Food and Drug Analysis |
| description | |
| discipline_display | Natural Sciences |
| discipline_facet | Natural Sciences |
| format | Online Article RSS Article |
| genre | Journal Article |
| id | rss_article:21734 |
| institution | FRELIP |
| journal_source_facet | Journal of Food and Drug Analysis |
| publishDate | 2025 |
| publishDateSort | 2025 |
| record_format | rss_article |
| spellingShingle | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. Biochemistry Natural Sciences — Physical Sciences Natural Sciences |
| sub_discipline_display | Natural Sciences — Physical Sciences |
| sub_discipline_facet | Natural Sciences — Physical Sciences |
| subject_display | Biochemistry Natural Sciences — Physical Sciences Natural Sciences Biochemistry Natural Sciences — Physical Sciences Natural Sciences |
| subject_facet | Biochemistry Natural Sciences — Physical Sciences Natural Sciences |
| title | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_auth | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_full | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_fullStr | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_full_unstemmed | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_short | Selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the AMPK/TFEB signaling pathway. |
| title_sort | selective sodium-glucose cotransporter two inhibitor empagliflozin ameliorates diabetic cardiomyopathy by activating the ampk/tfeb signaling pathway. |
| topic | Biochemistry Natural Sciences — Physical Sciences Natural Sciences |
| url | https://www.jfda-online.com/journal/vol33/iss4/6 |